Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-label, Uncontrolled, Multicentre, Rollover Study to Assess Safety and Efficacy of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency

NCT00596037 is registered in ClinicalTrials.gov with LG Life Sciences as lead sponsor.

NCT NCT00596037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00596037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-label, Uncontrolled, Multicentre, Rollover Study to Assess Safety and Efficacy of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency
Lead sponsor
LG Life Sciences
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2006
Completion date
May 31, 2009
Enrollment
136 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

adult growth hormone deficiency, pituitary disorders